Updated consensus statement on biological agents, specifically tumour necrosis factor α (TNFα) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004

被引：55
作者：
Furst, DE
Breedveld, FC
Kalden, JR
Smolen, JS
Burmester, GR
Bijlsma, JWJ
Dougados, M
Emery, P
Keystone, EC
Klareskog, L
Mease, PJ
机构：
[1] Univ Calif Los Angeles, Div Rheumatol, Los Angeles, CA USA
[2] Leiden Univ, Med Ctr, Dept Rheumatol, Leiden, Netherlands
[3] Univ Erlangen Nurnberg, Inst Clin Immunol, Dept Internal Med 3, Erlangen, Germany
[4] Vienna Gen Hosp, Clin Internal Med 3, Inst Rheumatol, Vienna, Austria
[5] Charite Hosp, Dept Rheumatol & Clin Immunol, Berlin, Germany
[6] Univ Utrecht, Med Ctr, Dept Rheumatol & Clin Immunol, Utrecht, Netherlands
[7] Hop Cochin, Inst Rhumatol, Paris, France
[8] Univ Leeds, Gen Infirm, Dept Rheumatol, Leeds LS1 3EX, W Yorkshire, England
[9] Mt Sinai Hosp, Dept Rheumatol, Toronto, ON, Canada
[10] Karolinska Hosp, Dept Med, Rheumatol Unit, S-10401 Stockholm, Sweden
[11] Swedish Med Ctr, Med Ctr, Seattle, WA USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2004年 / 63卷
关键词：
D O I：
10.1136/ard.2004.029272
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2 / 12
页数：11
相关论文
共 169 条
[1]   Experience with infliximab (anti-TNFα monoclonal antibody) as monotherapy for giant cell arteritis [J].
Andonopoulos, AP ;
Meimaris, N ;
Daoussis, D ;
Bounas, A ;
Giannopoulos, G .
ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 (11) :1116-1116
[2]   How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH [J].
Anker, SD ;
Coats, AJS .
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2002, 86 (2-3) :123-130
[3]   Open-label study of infliximab treatment for psoriatic arthritis: Clinical and magnetic resonance imaging measurements of reduction of inflammation [J].
Antoni, C ;
Dechant, C ;
Lorenz, PDHM ;
Wendler, J ;
Ogilvie, A ;
Lueftl, M ;
Kalden-Nemeth, D ;
Kalden, JR ;
Manger, B .
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2002, 47 (05) :506-512
[4]  
Antoni CE, 2001, ARTHRITIS RHEUM, V44, pS152
[5]  
Athreya BH, 2000, ARTHRITIS RHEUM, V43, pS117
[6]   Disease activity and risk of lymphoma in patients with rheumatoid arthritis:: nested case-control study [J].
Baecklund, E ;
Ekbom, A ;
Sparén, P ;
Feltelius, N ;
Klareskog, L .
BRITISH MEDICAL JOURNAL, 1998, 317 (7152) :180-181
[7]   Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease [J].
Baert, F ;
Noman, M ;
Vermeire, S ;
Van Assche, G ;
D'Haens, G ;
Carbonez, A ;
Rutgeerts, P .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (07) :601-608
[8]  
Baeten D, 2000, ARTHRITIS RHEUM, V43, pS404
[9]   Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease? [J].
Baeten, D ;
Kruithof, E ;
Van den Bosch, F ;
Van den Bossche, N ;
Herssens, A ;
Mielants, H ;
De Keyser, F ;
Veys, EM .
ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 (09) :829-834
[10]  
Baeten D, 2002, ARTHRITIS RHEUM-US, V46, pS432
12345678910